Literature DB >> 16356436

Cost of influenza hospitalization at a tertiary care children's hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months.

Jennifer L Hall1, Ben Z Katz.   

Abstract

OBJECTIVE: To calculate the costs of influenza hospitalization at a tertiary care children's hospital as the basis of a cost-benefit analysis of the new influenza vaccine recommendation for children age 6 to 23 months. STUDY
DESIGN: We reviewed the medical records of all patients admitted to Children's Memorial Hospital (CMH) in 2002 diagnosed with influenza. Total hospital costs were obtained from the Business Development Office.
RESULTS: Thirty-five charts were analyzed. Both of the 2 patients requiring mechanical ventilation and 4 of 6 patients admitted to the intensive care unit had high-risk underlying medical conditions. Nine children were age 6 to 23 months; 4 of these 9 had no preexisting medical conditions. Had all 18 high-risk children over age 6 months been protected from influenza, approximately $350,000 in hospital charges could have been saved.
CONCLUSIONS: Preventing the additional 4 hospitalizations in the otherwise low-risk children age 6 to 23 months for whom vaccine is currently recommended would have cost approximately $281,000 ($46/child) more than the hospital charges saved. When all children age 6 to 23 months are considered, influenza vaccination is less costly than other prophylactic measures. Addition of indirect costs, deaths, outpatient costs, and the cost of secondary cases would favor the cost:benefit ratio for influenza vaccination of all children age 6 to 23 months.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356436     DOI: 10.1016/j.jpeds.2005.06.031

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

2.  Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.

Authors:  Ruey-Kang R Chang; Alex Y Chen
Journal:  Pediatr Cardiol       Date:  2009-11-14       Impact factor: 1.655

3.  Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment.

Authors:  Frank Andersohn; Reinhard Bornemann; Oliver Damm; Martin Frank; Thomas Mittendorf; Ulrike Theidel
Journal:  GMS Health Technol Assess       Date:  2014-10-30

4.  Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age.

Authors:  Wanitchaya Kittikraisak; Piyarat Suntarattiwong; Darunee Ditsungnoen; Sarah E Pallas; Taiwo O Abimbola; Chonticha Klungthong; Stefan Fernandez; Suchada Srisarang; Tawee Chotpitayasunondh; Fatimah S Dawood; Sonja J Olsen; Kim A Lindblade
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

5.  Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions.

Authors:  Nargesalsadat Dorratoltaj; Achla Marathe; Bryan L Lewis; Samarth Swarup; Stephen G Eubank; Kaja M Abbas
Journal:  PLoS Comput Biol       Date:  2017-06-01       Impact factor: 4.475

6.  Health care costs of influenza-related episodes in high income countries: A systematic review.

Authors:  Carlo Federici; Marianna Cavazza; Francesco Costa; Claudio Jommi
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

7.  The clinical characteristics and direct medical cost of influenza in hospitalized children: a five-year retrospective study in Suzhou, China.

Authors:  Tao Zhang; Qiuli Zhu; Xuelan Zhang; Yunfang Ding; Mark Steinhoff; Steven Black; Genming Zhao
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

8.  Direct medical cost of influenza-related hospitalizations among severe acute respiratory infections cases in three provinces in China.

Authors:  Lei Zhou; Sujian Situ; Ting Huang; Shixiong Hu; Xianjun Wang; Xiaoping Zhu; Lidong Gao; Zhong Li; Ao Feng; Hui Jin; Shiyuan Wang; Qiru Su; Zhen Xu; Zijian Feng
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children.

Authors:  Stephen B Lambert; Kelly M Allen; Robert C Carter; Terence M Nolan
Journal:  Respir Res       Date:  2008-01-24

10.  Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.

Authors:  Cristina Carias; Carrie Reed; Inkyu K Kim; Ivo M Foppa; Matthew Biggerstaff; Martin I Meltzer; Lyn Finelli; David L Swerdlow
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.